Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple scan reveal hidden liver damage in diabetes patients?

NCT ID NCT04999124

Knowledge-focused Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

Researchers in Belgium are studying adults with type 2 diabetes to understand how often they develop non-alcoholic fatty liver disease (NAFLD) and what that condition looks like. Participants will undergo a liver scan, provide blood samples, and answer questionnaires about their physical activity, mood, and quality of life. The goal is to identify the typical features of NAFLD in this group, which could help doctors detect and manage liver problems earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could reveal how common and severe NAFLD is in type 2 diabetes patients, helping doctors identify who needs closer monitoring or earlier treatment.
What could go wrong
This is an observational study, so it cannot prove what causes NAFLD or test any treatment. The findings may not apply to all diabetes patients, only those seen in Belgian hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,762 people

The number who actually took part.

Started

Jan 2020

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-80 years, * having type 2 diabetes, * able to understand Dutch, * able to understand the informed consent Exclusion Criteria: * excessive alcohol abuse, * other liver disease, * secondary causes of steatosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease TYPE2 diabetes

Contacts and locations

Locations

  • Ziekenhuis Oost-Limburg

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.